Literature DB >> 11684348

Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia.

S Erhardt1, K Blennow, C Nordin, E Skogh, L H Lindström, G Engberg.   

Abstract

Kynurenic acid is an endogenous glutamate antagonist with a preferential action at the glycine-site of the N-methyl D-aspartate-receptor. Mounting evidence indicate that the compound is significantly involved in basal neurophysiological processes in the brain. In the present investigation, cerebrospinal fluid (CSF) level of kynurenic acid was analyzed in 28 male schizophrenic patients and 17 male healthy controls by means of high pressure liquid chromatography and fluorescence detection. Schizophrenic patients showed elevated CSF levels of kynurenic acid (1.67+/-0.27 nM) compared to the control group (0.97+/-0.07 nM). Furthermore, CSF levels of kynurenic acid in schizophrenic patients were also found to correlate with age. The present finding is indicative of a contribution of kynurenic acid in the pathogenesis of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11684348     DOI: 10.1016/s0304-3940(01)02242-x

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  169 in total

1.  Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.

Authors:  Surendra P Singh; Vidhi Singh
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

2.  3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia.

Authors:  Ruth Condray; George G Dougherty; Matcheri S Keshavan; Ravinder D Reddy; Gretchen L Haas; Debra M Montrose; Wayne R Matson; Joseph McEvoy; Rima Kaddurah-Daouk; Jeffrey K Yao
Journal:  Int J Neuropsychopharmacol       Date:  2011-01-28       Impact factor: 5.176

3.  Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine.

Authors:  Kathleen S Alexander; Hui-Qiu Wu; Robert Schwarcz; John P Bruno
Journal:  Psychopharmacology (Berl)       Date:  2011-10-26       Impact factor: 4.530

4.  Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood.

Authors:  Ana Pocivavsek; Hui-Qiu Wu; Greg I Elmer; John P Bruno; Robert Schwarcz
Journal:  Eur J Neurosci       Date:  2012-04-20       Impact factor: 3.386

5.  Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.

Authors:  Klas R Linderholm; Elisabeth Skogh; Sara K Olsson; Marja-Liisa Dahl; Maria Holtze; Göran Engberg; Martin Samuelsson; Sophie Erhardt
Journal:  Schizophr Bull       Date:  2010-08-20       Impact factor: 9.306

6.  Preferential Disruption of Prefrontal GABAergic Function by Nanomolar Concentrations of the α7nACh Negative Modulator Kynurenic Acid.

Authors:  Eden Flores-Barrera; Daniel R Thomases; Daryn K Cass; Ajay Bhandari; Robert Schwarcz; John P Bruno; Kuei Y Tseng
Journal:  J Neurosci       Date:  2017-07-20       Impact factor: 6.167

7.  Exposure to elevated embryonic kynurenine in rats: Sex-dependent learning and memory impairments in adult offspring.

Authors:  Silas A Buck; Annalisa M Baratta; Ana Pocivavsek
Journal:  Neurobiol Learn Mem       Date:  2020-07-30       Impact factor: 2.877

Review 8.  Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

Authors:  Sophie Erhardt; Sara K Olsson; Göran Engberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 9.  Lysine metabolism in mammalian brain: an update on the importance of recent discoveries.

Authors:  André Hallen; Joanne F Jamie; Arthur J L Cooper
Journal:  Amino Acids       Date:  2013-09-17       Impact factor: 3.520

10.  The effect of transient increases in kynurenic acid and quinolinic acid levels early in life on behavior in adulthood: Implications for schizophrenia.

Authors:  Hannah F Iaccarino; Raymond F Suckow; Shan Xie; David J Bucci
Journal:  Schizophr Res       Date:  2013-09-30       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.